Implantable Cardioverter-defibrillator

The system continuously evaluates cardiac electrical activity against programmed criteria. When those criteria indicate a life-threatening rhythm, available therapies include antitachycardia pacing and an electrical shock. This decision process links detection to treatment while preserving normal heartbeats from therapy when the programmed criteria do not identify a dangerous rhythm.

Programmed detection criteria act as the decision threshold for therapy. The ICD analyzes cardiac electrical activity and delivers treatment only when the pattern meets criteria indicating a life-threatening rhythm. This selective logic supports intervention during ventricular tachycardia or ventricular fibrillation while avoiding therapy for normal heartbeats.

Continuous analysis allows the device to assess cardiac electrical activity over time rather than relying on an isolated clinical observation. That ongoing surveillance supports programmed decisions about therapy and provides information for follow-up. Clinicians can use this continuing device-based assessment as part of individualized risk management.

Management is individualized according to the reason a patient is considered at high risk, such as previous cardiac arrest, impaired ventricular function, or an inherited rhythm disorder. Implantation, programming, and follow-up are organized around that risk profile, allowing clinicians to combine device therapy with continuing information for risk management.

Implantation places the device beneath the skin and connects it to the heart with leads. After placement, clinicians program the system so its detection and treatment criteria reflect the intended care plan. Follow-up then supports review of device information and continued individualized management as the patient’s risk is monitored over time.

Clinical consideration centers on elevated risk of sudden cardiac death. Circumstances identified in the clinical context include previous cardiac arrest, impaired ventricular function, and inherited rhythm disorders. These factors help clinicians assess whether an ICD fits the patient’s risk profile and prevention strategy rather than applying the same approach to every person with an arrhythmia.

Follow-up provides device data for ongoing risk management. Those data are considered alongside the patient’s clinical context, including the reason for elevated sudden-death risk and the programmed approach to therapy. This continuing review supports individualized care after implantation, rather than treating the procedure as the endpoint of clinical management.